Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2005

01-05-2005 | Short Communication

Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin

Authors: Milly E. de Jonge, Alwin D. R. Huitema, Selma M. van Dam, Jos H. Beijnen, Sjoerd Rodenhuis

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2005

Login to get access

Abstract

Patient and method

A 42-year-old male patient with relapsing germ-cell cancer was enrolled in a salvage protocol that employed two 4-day courses of CTC high-dose chemotherapy with cyclophosphamide (1,500 mg m−2 day−1), thiotepa (120 mg m−2 day−1), and carboplatin, followed by peripheral blood progenitor cell support. From five days before the start of the second CTC course the patient received phenytoin for generalized epileptic seizures. Blood samples were collected on day 1 of both CTC courses and analyzed for cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide, and for thiotepa and its main active metabolite tepa.

Results

Exposure (expressed as area under the plasma concentration vs time curve) to 4-hydroxycyclophosphamide and tepa in the second CTC course was increased by 51% and 115%, respectively, compared with the first CTC course, whereas exposure to cyclophosphamide and thiotepa was significantly reduced (67% and 29%, respectively). Because high exposure to 4-hydroxycyclophosphamide and tepa correlates with increased toxicity, the treatment risk of this patient was significantly increased. Therefore doses were reduced on the third day of the second course.

Conclusion

It was concluded that phenytoin significantly induces both cyclophosphamide and thiotepa metabolism, most probably by induction of the cytochrome p450 enzyme system. This potential clinical significant interaction should be taken into account when phenytoin is administered in combination with cyclophosphamide and thiotepa in clinical practice.
Literature
1.
Chang TKH, Weber GF, Crespi CL et al (1993) Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 53:5629–5637PubMed
2.
De Jonge ME, Huitema ADR, Van Dam SM et al (2003) Pharmacokinetically guided dosing of cyclophosphamide, thiotepa and carboplatin in high dose chemotherapy. Proc Am Soc Clin Oncol 22:140 (abstr)
3.
De Jonge ME, Huitema ADR, Rodenhuis S et al (2004) Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug–drug interaction. J Pharmacokin Pharmacodyn 31:135–156CrossRef
4.
De Jonge ME, Van Dam SM, Hillebrand MJX et al (2004) Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N′,N″-triethylenethiophosphoramide (thiotepa) and N,N′,N″-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Mass Spectrom 39:233–254CrossRefPubMed
5.
Ducharme MP, Bernstein ML, Granvil et al (1997) Phenytoin-induced alteration in the N-dechloroethylation of ifosfamide stereoisomers. Cancer Chemother Pharmacol 40:531–533CrossRef
6.
Heideman RL, Cole DE, Balis F et al (1989) Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res 49:736–741
7.
Huitema ADR, Spaander M, Mathôt RAA et al (2002) Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thioTEPA and carboplatin. Ann Oncol 13:374–384CrossRef
8.
Jacobson PA, Green K, Birnbaum A et al (2002) Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to tepa. Cancer Chemother Pharmacol 49:461–467CrossRef
9.
LeCluyse EL, Ribadeneira MD, Diamond S et al (1996) Induction of CYP1A, CYP2A, CYP2B, CYP2C, and CYP3A by various drugs and prototypical inducers in primary cultures of human hepatocytes. ISSX Proc 10:196
10.
Nation RL, Evans AM, Mike RW et al (1990) Pharmacokinetics drug interactions with phenytoin. Part I and II. Clin Pharmacokinet 18:37–60 (see also pages 131–150)
11.
Petros WP, Broadwater G, Berry D et al (2002) Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 8:698–705
12.
Pichard L, Fabre I, Fabre G et al (1990) Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595–606
13.
Relling MV, Pui CH, Sandlund JT et al (2000) Adverse effects of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukemia. Lancet 356:285–290CrossRef
14.
Ren S, Yang JS, Kalhorn TF et al (1997) Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 57:4229–4235
15.
Rodenhuis S, Westerman A, Holtkamp MJ et al (1996) Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 14:1473–1483
16.
Rodenhuis S, De Wit R, De Mulder PHM et al (1999) A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 10:1467–1473CrossRef
17.
Rodenhuis S, Bontenbal M, Beex LV et al (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349:7–16CrossRef
18.
Roy P, Yu LJ, Crespi CL et al (1999) Development of a substrate activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos 27:655–666
19.
Schrama JG, Holtkamp MJ, Baars JW et al (2003) Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience. Br J Cancer 88:1831–1838CrossRef
20.
Slattery JT, Kalhorn TF, McDonald GB et al (1996) Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 14:1484–1494
21.
Spaans E, Van Den Heuvel MW, Schnabel PG et al (2002) Concomitant use of mirtazapine and phenytoin: a drug–drug interaction study in healthy male subjects. Eur J Clin Pharmacol 58:423–429CrossRef
22.
Teicher BA, Waxman DJ, Holden SA et al (1989) Evidence for enzymatic activation and oxygen involvement in cytotoxicity and anti-tumor activity of N,N′,N″-triethylenethiophosphoramide. Cancer Res 49:4996–5001
23.
Thummel KE, Shen DD, Podoll T et al (1994) Use of midazolam as a human cytochrome P-450 3A probe. II. Characterization of inter- and intra-individual variability following liver transplantation. J Pharmacol Exp Ther 271:557–566
24.
Van Warmerdam LJC, Van Tellingen O, Maes RAA et al (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 352:777–781CrossRef
25.
Yu L, Waxman J (1996) Role of cytochrome P450 in oxazaphosphorine metabolism. Deactivation via N-dechloroethylation and activation via 4-hydroxylation catalyzed by distinct subsets of rat liver cytochromes P450. Drug Metab Dispos 24:1254–1262
Metadata
Title
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin
Authors
Milly E. de Jonge
Alwin D. R. Huitema
Selma M. van Dam
Jos H. Beijnen
Sjoerd Rodenhuis
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2005
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0922-y

Other articles of this Issue 5/2005

Cancer Chemotherapy and Pharmacology 5/2005 Go to the issue

Original Article

Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

Original Article

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

Original Article

Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis

Original Article

Uptake of irinotecan metabolite SN-38 by the human intestinal cell line Caco-2

Original Article

Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors

Original Article

EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits